You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 11, 2024

Bromocriptine mesylate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for bromocriptine mesylate and what is the scope of patent protection?

Bromocriptine mesylate is the generic ingredient in three branded drugs marketed by Lek Pharm, Mylan, Zydus Pharms Usa Inc, Esjay Pharma, Aurobindo Pharma Usa, Padagis Us, Sandoz, and Veroscience, and is included in eight NDAs. There are thirteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Bromocriptine mesylate has thirty-three patent family members in thirteen countries.

There are eight drug master file entries for bromocriptine mesylate. Eight suppliers are listed for this compound.

Summary for bromocriptine mesylate
International Patents:33
US Patents:13
Tradenames:3
Applicants:8
NDAs:8
Drug Master File Entries: 8
Finished Product Suppliers / Packagers: 8
Raw Ingredient (Bulk) Api Vendors: 53
Clinical Trials: 6
Drug Prices: Drug price trends for bromocriptine mesylate
What excipients (inactive ingredients) are in bromocriptine mesylate?bromocriptine mesylate excipients list
DailyMed Link:bromocriptine mesylate at DailyMed
Drug Prices for bromocriptine mesylate

See drug prices for bromocriptine mesylate

Recent Clinical Trials for bromocriptine mesylate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Andrew Moshfeghi, MD, MBAPhase 1/Phase 2
Case Western Reserve UniversityPhase 1/Phase 2
VeroSciencePhase 1

See all bromocriptine mesylate clinical trials

Pharmacology for bromocriptine mesylate
Drug ClassErgot Derivative
Medical Subject Heading (MeSH) Categories for bromocriptine mesylate

US Patents and Regulatory Information for bromocriptine mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Padagis Us BROMOCRIPTINE MESYLATE bromocriptine mesylate TABLET;ORAL 077646-001 Oct 1, 2008 AB RX No Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Mylan BROMOCRIPTINE MESYLATE bromocriptine mesylate CAPSULE;ORAL 077226-001 Apr 4, 2005 AB RX No Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for bromocriptine mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 ⤷  Sign Up ⤷  Sign Up
Esjay Pharma PARLODEL bromocriptine mesylate CAPSULE;ORAL 017962-002 Mar 1, 1982 ⤷  Sign Up ⤷  Sign Up
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 ⤷  Sign Up ⤷  Sign Up
Esjay Pharma PARLODEL bromocriptine mesylate TABLET;ORAL 017962-001 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for bromocriptine mesylate

Country Patent Number Title Estimated Expiration
Australia 2010256366 Combination of dopamine agonists plus first phase insulin secretagouges for the treatment of metabolic disorders ⤷  Sign Up
Australia 2016202572 BROMOCRIPTINE FORMULATIONS ⤷  Sign Up
Australia 2018203021 ⤷  Sign Up
Hong Kong 1208173 溴麥角環肽製劑 (BROMOCRIPTINE FORMULATIONS) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.